2025-12-23 - Analysis Report
Okay, here's a breakdown of the Teladoc Health Inc (TDOC) data you provided, followed by a comprehensive analysis:

**1) Return Rate Comparison: TDOC vs. S&P 500 (VOO)**

*   **TDOC Company Overview:** Teladoc Health Inc. is a telehealth company that provides virtual healthcare services.

*   **TDOC Cumulative Return:** -64.26%
*   **VOO (S&P 500) Cumulative Return:** 101.92%
*   **Divergence:** -166.2 (Relative Divergence: 0.1)

**Analysis:** TDOC has significantly underperformed the S&P 500. The -166.2 divergence means TDOC's performance is drastically behind the market benchmark. The relative divergence of 0.1 suggests that this divergence is near its worst point in the historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha    | Beta  | Cap(B) |
|------------|--------|-------|----------|-------|--------|
| 2015-2017  | 77.0%  | 70.4% | 51.0%    | -0.1  | 6.2    |
| 2016-2018  | 101.0% | 69.4% | 86.0%    | -0.1  | 8.8    |
| 2017-2019  | 141.0% | 73.8% | 118.0%   | 0.3   | 14.9   |
| 2018-2020  | 105.0% | 80.9% | 81.0%    | 0.3   | 35.6   |
| 2019-2021  | -78.0% | 80.9% | -125.0%  | 0.3   | 16.4   |
| 2020-2022  | -252.0%| 85.9% | -251.0%  | -0.9  | 4.2    |
| 2021-2023  | -315.0%| 85.9% | -316.0%  | -1.8  | 3.8    |
| 2022-2024  | -93.0% | 85.9% | -113.0%  | -1.9  | 1.6    |
| 2023-2025  | -35.0% | 81.6% | -101.0%  | -0.8  | 1.3    |

**Analysis:**

*   **CAGR:** Compounded Annual Growth Rate was very strong early on but has turned sharply negative in recent years.
*   **MDD:** Maximum Drawdown remains very high, indicating significant risk and volatility.
*   **Alpha:** The Alpha, representing performance above the benchmark, has plummeted into deeply negative territory, indicating considerable underperformance relative to the market.
*   **Beta:** The Beta has become more negative, suggesting an inverse correlation with the market in more recent years. A negative beta is unusual and potentially concerning.
*   **Cap(B):** Market Cap in Billions has declined heavily

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 7.23
*   **Last Market Data:** Price 7.26, Previous Close 7.23, Change 0.41
*   **5-day SMA:** 7.27
*   **20-day SMA:** 7.44
*   **60-day SMA:** 7.91

**Analysis:** The stock price is below all three Simple Moving Averages (SMAs), which suggests a short-term downtrend. The slight increase in price and change in the last market is a positive sign, but it's not enough to reverse the downtrend, yet.

**3) Market Risk Indicators and Expected Return:**

*   **MRI:** 0.8 (Medium Investment)
*   **RSI:** 39.19 (approaching oversold)
*   **PPO:** -0.18 (Negative, indicating a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (132 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.3 (Short-term decline)
*   **Expected Return (%):** -10382.5% (Very Negative)

**Analysis:**

*   While the MRI suggests a medium investment opportunity, other indicators paint a less optimistic picture.
*   The RSI is approaching oversold conditions, which *could* indicate a potential bounce, but doesn't guarantee it.
*   The negative PPO confirms the downtrend.
*   The *extremely* negative expected return suggests that, according to this model, long-term investment in TDOC from this point is projected to significantly underperform the S&P 500.

**4) Recent News & Significant Events:**

*   **Positive:** Several articles highlight analyst coverage initiation with an "Equal Weight" rating and a target price of $8.50, suggesting some analysts see limited upside but also limited downside.  An article also suggests a potential "major upside" based on DCF (Discounted Cash Flow) analysis, potentially seeing the stock as undervalued.
*   **Neutral/Negative:**  The news of a CLO selling shares is generally considered negative, as it can signal a lack of confidence from an insider. The consensus rating of "Hold" indicates that analysts, on average, are not strongly recommending buying or selling.
*   **Mixed:** Overall, the news is mixed. Some articles point to potential undervaluation, while others suggest caution.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.67 (~Hold)
*   **Opinions:** 22
*   **Target Price:** Avg 9.18 / High 12.00 / Low 7.00
*   **Recent Rating Changes:** No provided changes

**Analysis:** The analyst consensus is "Hold," suggesting no strong buy or sell recommendation. The average target price ($9.18) represents a potential upside from the current price, but the range ($7.00 - $12.00) is wide, indicating uncertainty.

**5) Recent Earnings Analysis:**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-10-30 | -0.28 | 0.63 B$    |
| 2025-07-30 | -0.19 | 0.63 B$    |
| 2025-05-01 | -0.53 | 0.63 B$    |
| 2024-10-31 | -0.19 | 0.64 B$    |
| 2025-10-30 | -0.19 | 0.64 B$    |

**Analysis:**

*   TDOC is consistently reporting negative EPS (Earnings Per Share).
*   Revenue has been relatively stable around $0.63 - $0.64 billion.
*   The continued losses are a significant concern.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.63B  | 70.12%        |
| 2025-06-30   | $0.63B  | 69.85%        |
| 2025-03-31   | $0.63B  | 68.73%        |
| 2024-12-31   | $0.64B  | 70.50%        |
| 2024-09-30   | $0.64B  | 71.94%        |

Capital and Profitability:

| Quarter      | Equity  | ROE       |
|--------------|---------|-----------|
| 2025-09-30   | $1.39B  | -3.56%    |
| 2025-06-30   | $1.42B  | -2.30%    |
| 2025-03-31   | $1.43B  | -6.52%    |
| 2024-12-31   | $1.49B  | -3.25%    |
| 2024-09-30   | $1.51B  | -2.21%    |

**Analysis:**

*   **Revenue:** Revenue is stable, showing little growth.
*   **Profit Margin:** Profit margins are relatively high.
*   **Equity:** Equity is declining, which could be a concern.
*   **ROE:** Return on Equity is consistently negative, reflecting the company's inability to generate profits for its shareholders.

**7) Comprehensive Analysis (Summary):**

TDOC's performance is concerning.

*   It has significantly underperformed the S&P 500, with a large negative divergence.
*   Financial performance shows consistent losses (negative EPS and ROE) and declining equity.
*   Technical indicators suggest a short-term downtrend and potential oversold conditions.
*   While analyst opinions are neutral ("Hold"), the wide target price range indicates uncertainty.
*   The mixed news flow suggests both potential undervaluation and ongoing challenges.

**Overall Recommendation:**

Based on this data, a *cautious* approach is warranted. While there are some potential positive signs (potential oversold conditions, some analyst target prices), the overwhelming picture is one of underperformance, financial losses, and ongoing challenges.

**Before making any investment decisions, it is crucial to conduct further due diligence, considering your own risk tolerance and investment objectives.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.